MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 74 filers reported holding MARINUS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,608,925 | -24.6% | 324,090 | +1.7% | 0.00% | – |
| Q2 2023 | $3,460,181 | -24.8% | 318,617 | -52.2% | 0.00% | -100.0% |
| Q1 2023 | $4,601,645 | +71.9% | 666,905 | -0.9% | 0.00% | – |
| Q4 2022 | $2,677,207 | +126.5% | 672,665 | +278.1% | 0.00% | – |
| Q3 2022 | $1,182,000 | +79.4% | 177,905 | +30.7% | 0.00% | – |
| Q2 2022 | $659,000 | -68.1% | 136,066 | -38.5% | 0.00% | – |
| Q1 2022 | $2,067,000 | -66.8% | 221,098 | -57.8% | 0.00% | – |
| Q4 2021 | $6,226,000 | +75.2% | 524,168 | +67.9% | 0.00% | – |
| Q3 2021 | $3,553,000 | -56.6% | 312,233 | -31.5% | 0.00% | -100.0% |
| Q2 2021 | $8,181,000 | -26.8% | 456,053 | -36.9% | 0.00% | -50.0% |
| Q1 2021 | $11,182,000 | -45.6% | 722,385 | -57.1% | 0.00% | 0.0% |
| Q4 2020 | $20,550,000 | +170.3% | 1,684,492 | +184.7% | 0.00% | 0.0% |
| Q3 2020 | $7,602,000 | – | 591,597 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 3,629,622 | $33,936,000 | 7.88% |
| VR Adviser, LLC | 3,156,803 | $29,516,000 | 4.78% |
| Bleichroeder LP | 1,322,463 | $12,365,000 | 2.19% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $13,380,000 | 1.30% |
| 683 Capital Management, LLC | 1,932,829 | $18,072,000 | 0.97% |
| Granite Point Capital Management, L.P. | 472,056 | $4,414,000 | 0.92% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2,766,000 | $25,862,000 | 0.79% |
| Avoro Capital Advisors LLC | 3,150,000 | $29,453,000 | 0.54% |
| Artal Group S.A. | 1,000,000 | $9,350,000 | 0.39% |
| Stonepine Capital Management, LLC | 56,747 | $531,000 | 0.22% |